Avilex Pharma is a spin out from
the University of Copenhagen, founded by
Professor Kristian Strømgaard and Dr Anders Bach of the Department of Drug Design and Pharmacology,
with seed investment from Novo Seeds (part of Novo A/S).
Avilex Pharma is developing novel inhibitors of PDZ domains to target a range of unmet medical needs.
For further information, please contact
Professor Kristian Strømgaard, CEO
+45 3533 6114